treatment group – Page 15 – Communicable Diseases Research

Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19

Observational Study

Published on 2020-11-012022-10-05
Journal: Clinical and translational science [Category] SARS, 임상,

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

COVID-19로 병원에 입원한 환자의 Lopinavir-ritonavir(RECOVERY): 무작위, 통제, 공개, 플랫폼 시험

Randomized Controlled Trial

Published on 2020-10-242022-08-13
Journal: Lancet (London, England) [Category] 임상,

[키워드] 28-day mortality 95% CI active treatment all-cause mortality allocation concealment assigned Azithromycin baseline both groups by mouth composite endpoint death Dexamethasone died discharge discharged eligible finding funding groups hospital Hospital stay Hydroxychloroquine IMPROVE in both groups in vitro activity intention-to-treat basis Invasive mechanical ventilation ISRCTN Lopinavir Lopinavir–ritonavir median Medical Research Council mouth no significant difference observational studies Open-label outcome Participants Patient Platform trial preclinical studies Primary outcome proportion randomisation randomised Randomised trial Randomly rate ratio receive recovery reductions reductions in Registered Result risk risk ratio Ritonavir Standard of care subgroups of patients Support the patient treat Treatment treatment for COVID-19 treatment group Trial usual care web-based simple with COVID-19
[DOI] 10.1016/S0140-6736(20)32013-4 PMC 바로가기 [Article Type] Randomized Controlled Trial

Is health politically irrelevant? Experimental evidence during a global pandemic

Original Research

Published on 2020-10-232022-10-28
Journal: BMJ Global Health [Category] Coronavirus, MERS, SARS,

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection – a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-202022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 2019-nCoV allergic Antipyretic Antiretroviral therapy Antiviral Arm as required assigned Breastfeeding Care categories cause clinical combination therapy compassionate use cough country COVID-19 COVID-19 infection criteria death defined described discharged disease dissemination drug Efficacy element eligibility criteria enrolled enrolment Etiquette exclusion criteria exploratory female Fever Frequency H1N1 hand hygiene Hydration Hydroxychloroquine ICU Patients inclusion criteria India Infection infection with SARS-CoV-2 investigator Laboratory Loading dose Lopinavir/ritonavir Lopinavir/Ritonavir combination mechanical ventilation medication Mortality non-ICU non-invasive ventilation Non-severe case Normalisation number nutrition objective off-label organ oxygen saturation paO2/fiO2 participant Participants Patient pharmacotherapy Placebo positive Precaution progression protocol QT prolongation randomisation randomised randomised controlled trial randomization Randomized controlled trial Randomly receipt recruitment regimen Registration registry replaced required Research respiratory rate ribavirin RT-PCR Safety Sample size SARS-CoV-2 RT-PCR screened secondary secure Serious Adverse Event Severe COVID-19 Infection Severe patient severity specimen Standard standard treatment status stratified study period Study protocol supplemental oxygen Support Suppressant surgical sustained symptomatic patient Tablet tested the patient therapeutic intervention therapy time time to defervescence treated Treatment treatment arm treatment group Trial upper respiratory tract Vasopressor Ventilation ventilator wear website
[DOI] 10.1186/s13063-020-04774-5 PMC 바로가기 [Article Type] Letter

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-132022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter

Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19

COVID-19에 대한 비교 임상 연구에서 치료 효과를 평가하기 위한 적절한 종료점 선택

Article

Published on 2020-10-012022-09-11
Journal: Contemporary clinical trials [Category] SARS, 임상, 치료법,

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Research

Published on 2020-09-242022-10-28
Journal: Virology Journal [Category] COVID-19, SARS,

[키워드] 95% CI adverse effect adverse effects Antiviral Antiviral agents clinical Clinical improvement conducted control group coronavirus COVID-19 COVID-19 drug treatment criteria database Deterioration Efficacy and safety Endpoint enzyme Favipiravir FVP Google Scholar inhibit less Meta-analysis Negative conversion no significant difference non-invasive ventilation not significant Oxygen requirement oxygen support profiles purine quantitative synthesis radiological improvement Randomized controlled trial RCTs Registered Replication Result RNA RNA polymerase RNA virus RT-PCR searched severe acute respiratory syndrome coronavirus-2 Side effect Standard of care statistically supportive care systematic review Treatment treatment for COVID-19 treatment group two group viral clearance was done
[DOI] 10.1186/s12985-020-01412-z PMC 바로가기 [Article Type] Research

Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19

Clinical Study

Published on 2020-09-232022-10-27
Journal: BioMed Research International [Category] COVID-19,

[키워드] Admission blood lymphocyte CD3+ CD4+ CD4+ T cell CD8+ CD8+ T cell China clearance Clinical outcome conducted COVID-19 COVID-19 case cross-sectional cumulative disease Effect effect size evaluate Final glucocorticoid Glucocorticoids group healthy individuals low-dose lymphocyte Lymphocyte count Methylprednisolone Mild mild COVID-19 patients Negative conversion rate no significant difference nucleic acid objective patients peripheral Peripheral blood peripheral lymphocyte Pharyngeal swab positive Result retrospective returned significantly single-center study statistically significant T cell T cell subset T cells the disease the healthy the patient treatment group treatment groups two groups viral nucleic acid were recorded were used without affecting
[DOI] 10.1155/2020/2854186 PMC 바로가기 [Article Type] Clinical Study

Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19

Clinical Study

Published on 2020-09-232022-10-27
Journal: BioMed Research International [Category] Coronavirus, COVID-19, MERS, SARS,

[키워드] Admission blood lymphocyte CD3+ CD4+ CD4+ T cell CD8+ CD8+ T cell China clearance Clinical outcome conducted COVID-19 COVID-19 case cross-sectional cumulative disease Effect effect size evaluate Final glucocorticoid Glucocorticoids group healthy individuals low-dose lymphocyte Lymphocyte count Methylprednisolone Mild mild COVID-19 patients Negative conversion rate no significant difference nucleic acid objective patients peripheral Peripheral blood peripheral lymphocyte Pharyngeal swab positive Result retrospective returned significantly single-center study statistically significant T cell T cell subset T cells the disease the healthy the patient treatment group treatment groups two groups viral nucleic acid were recorded were used without affecting
[DOI] 10.1155/2020/2854186 PMC 바로가기 [Article Type] Clinical Study

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Clinical Trial

Published on 2020-09-212022-10-27
Journal: Antimicrobial Agents and Chemotherapy [Category] Coronavirus, COVID-19, SARS,

[키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical conducted Cooperative COVID-19 death Disease progression Endpoint enrolled Favipiravir Fever group hospital IMPROVE in viral Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza viral clearance with COVID-19
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial